Drugging the Undruggable: Million-Fold Leap Targets Prostate Cancer’s Elusive Androgen Receptor

/in /by

Prostate cancer treatments have hit a wall with castration-resistant cases, where tumors keep growing despite hormone blockers targeting the androgen receptor’s stable parts. A new study from University of British Columbia and BC Cancer researchers published on Nature cracks that open by hitting the receptor’s “undruggable” intrinsically disordered transactivation domain (NTD/TAD), the flexible region that […]

Read more

DNA Smart Drugs: Precision Cancer Treatment With a Double Lock

/in , /by

A new study in Nature Biotechnology describes a DNA-based drug system that can turn on only when it finds the right combination of markers on a cancer cell. This matters because many cancer drugs are powerful but also damage healthy tissue, so the main challenge is not only killing the tumor, but doing it with […]

Read more

A PSMA‑Targeted CAR‑T Cell Therapy with CD16A Signaling for Prostate Cancer

/in , /by

Adoptive transfer of chimeric antigen receptor (CAR) T cells has worked well in some blood cancers, but it has been much less effective in solid tumors like prostate cancer. One reason is the strong cytokine release and strong immune suppression in the tumor area. A new study has designed a PSMA‑targeted CAR that uses CD16A, […]

Read more

CEACAM5 Radiotheranostics: A Targeted Strategy for PSMA-Negative, Neuroendocrine Prostate Cancer

/in , /by

For prostate cancer patients with low expression of PSMA or with neuroendocrine prostate cancer or NEPC (a population growing in size precisely because better treatments are forcing tumors to adapt), a new preclinical study offers a credible precision-targeted strategy: a radiotheranostic pair built on the CEACAM5 surface antigen that produced complete tumor responses in every […]

Read more

ITRI-148: A Next-Generation AR Degrader Targeting Resistance at Its Core

/in , /by

A new experimental compound, ITRI-148, may represent a meaningful shift in how advanced prostate cancer is treated, particularly in patients who develop resistance to current androgen receptor (AR)-targeted therapies. Resistance to drugs like enzalutamide is frequently driven by AR splice variants such as AR-V7, which lack the ligand-binding domain (LBD) targeted by existing therapies, allowing […]

Read more

ProTCE-PSMA Pushes PSMA T-Cell Engagers Toward a Safer Therapeutic Window

/in , /by

A new generation of PSMA-targeted T-cell engagers is emerging with a clear goal: preserve the potency seen in hematologic malignancies while overcoming the safety and efficacy barriers that have limited success in solid tumors. A preclinical candidate, ProTCE-PSMA, presented ahead of IND filing in early 2026, illustrates how rapidly this field is evolving beyond first-generation […]

Read more

Helicon Peptides: Degrading Active AR to Overcome Prostate Cancer Resistance

/in /by

Current AR therapies like enzalutamide target the inactive, unliganded AR conformation (AROFF) by binding its androgen pocket, preventing activation but leaving already active, agonist-bound AR (ARON), the real driver of tumor transcription and proliferation, untouched. This allows resistant tumors to adapt through AR gene amplification, mutations in the ligand-binding domain, or alternative activation pathways, leading […]

Read more

AM109: A PSMA‑Targeted CD137 Bispecific Antibody for Metastatic Castration‑Resistant Prostate Cancer (mCRPC / mAPMR)

/in , /by

AM109 is designed as a bispecific agent that links a PSMA‑targeting humanized antibody to a CD137 (4‑1BB)‑targeting affibody, effectively creating a molecular bridge between prostate cancer cells and T cells in the tumor microenvironment. The rationale is straightforward: by restricting CD137 activation to sites where PSMA is expressed, the therapy aims to drive potent anti‑tumor […]

Read more

A nano-PROTAC on the horizon: combining targeted protein degradation and ferroptosis for advanced prostate cancer

/in , /by

A new study from Wuhan University and the Renmin Hospital of Wuhan University has reported a promising preclinical strategy for advanced prostate cancer, especially castration-resistant prostate cancer (CRPC). The work was published online in Angewandte Chemie International Edition, one of the leading international journals in chemistry. The study describes a new nano-PROTAC platform designed to […]

Read more

A New Drug Candidate TB511 Shows Promise for Hard-to-Treat Prostate Cancer

/in , /by

Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune […]

Read more